Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 12/20 | 1.00 |
| ▸ | CA9 | Q16790 | 12/20 | 1.00 |
| ▸ | CA1 | P00915 | 9/20 | 1.00 |
| ▸ | CA4 | P22748 | 7/20 | 1.00 |
| ▸ | MAOA | P21397 | 8/20 | 0.72 |
| ▸ | MAOB | P27338 | 8/20 | 0.72 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.68 |
| ▸ | CA6 | P23280 | 5/20 | 0.65 |
| ▸ | CA7 | P43166 | 5/20 | 0.65 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.65 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.65 |
| ▸ | CA5A | P35218 | 3/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | GLA | P06280 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | CA2 | P00918 | 3/20 | 0.61 |
| ▸ | CA3 | P07451 | 3/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30127638 | 1.00 | CA12 (1.00) | CA12CA9CA1CA4MAOA | |
| SCHEMBL5904507 | 0.89 | CA12 (1.00) | CA12CA9CA1CA4MAOA | |
| SCHEMBL8515698 | 0.84 | MAOA (1.00) | CA12CA9CA1CA4MAOA | |
| 7-(2-Butynyloxy)Coumarin SCHEMBL17682923 | 0.82 | MTNR1A (0.77) | CA12CA9CA1CA4MAOA | |
| SCHEMBL12304245 | 0.82 | CA12 (0.81) | CA12CA9CA1CA4MAOA | |
| SCHEMBL8512831 | 0.81 | CA12 (1.00) | CA12CA9CA1CA4MAOA | |
| 7-(2-Pentynyloxy)Coumarin SCHEMBL18292783 | 0.81 | MTNR1A (1.00) | CA12CA9CA1CA4MAOA | |
| SCHEMBL17679806 | 0.80 | MTNR1A (0.73) | CA12CA9CA1CA4MAOA | |
| SCHEMBL22017341 | 0.80 | CA12 (0.66) | CA12CA9CA1CA4MAOA | |
| SCHEMBL11502238 | 0.80 | MAOB (0.66) | CA12CA9CA1CA4MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250215028-A1 | SYNTHETIC GLYCEROPHOSPHOLIPIDS COMPRISING AT LEAST ONE REACTIVE FUNCTION, PROCESS FOR PREPARING SAME AND USES THEREOF IN DIFFERENT APPLICATIONS | UNIVERSITE DE ROUEN-NORMANDIE (FR) | 2025-07-03 | — | — | US | disclosed |
| EP-4499652-A1 | SYNTHETIC GLYCEROPHOSPHOLIPIDS COMPRISING AT LEAST ONE REACTIVE FUNCTION, PROCESS FOR PREPARING SAME AND USES THEREOF IN DIFFERENT APPLICATIONS | Universite de Rouen Normandie (FR) | 2025-02-05 | — | — | EP | disclosed |
| US-20240213536-A1 | Lithium Secondary Battery | LG ENERGY SOLUTION, LTD. (KR) | 2024-06-27 | — | — | US | disclosed |
| US-20240213536-A1 | Lithium Secondary Battery | LG ENERGY SOLUTION, LTD. (KR) | 2024-06-27 | — | — | US | disclosed |
| EP-4329038-A1 | NON-AQUEOUS ELECTROLYTE COMPRISING ADDITIVE FOR NON-AQUEOUS ELECTROLYTE, AND LITHIUM SECONDARY BATTERY COMPRISING SAME | LG Energy Solution, Ltd. (KR) | 2024-02-28 | — | — | EP | disclosed |
| EP-4329040-A1 | NON-AQUEOUS ELECTROLYTE FOR LITHIUM SECONDARY BATTERY AND LITHIUM SECONDARY BATTERY COMPRISING SAME | LG Energy Solution, Ltd. (KR) | 2024-02-28 | — | — | EP | disclosed |
| US-11862764-B2 | Non-aqueous electrolyte comprising additive for non-aqueous electrolyte, and lithium secondary battery comprising the same | LG ENERGY SOLUTION, LTD. | 2024-01-02 | — | — | US | disclosed |
| CN-117337507-A | Nonaqueous electrolyte containing additive for nonaqueous electrolyte and lithium secondary battery containing same | 株式会社LG新能源 | 2024-01-02 | — | — | CN | disclosed |
| US-11862764-B2 | Non-aqueous electrolyte comprising additive for non-aqueous electrolyte, and lithium secondary battery comprising the same | LG ENERGY SOLUTION, LTD. | 2024-01-02 | — | — | US | disclosed |
| WO-2023219474-A1 | NON-AQUEOUS ELECTROLYTE AND LITHIUM SECONDARY BATTERY COMPRISING SAME | 주식회사 엘지에너지솔루션 | 2023-11-16 | — | — | WO | disclosed |
| WO-2014205414-A1 | EXPANDED THERAPEUTIC POTENTIAL IN NITROHETEROARYL ANTIMICROBIALS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-12-24 | — | — | WO | disclosed |
| WO-2014194250-A2 | NOVEL NANOCARRIER DELIVERED CANCER CHEMOTHERAPEUTIC AGENTS | UNIVERSITY OF CINCINNATI (US) | 2014-12-04 | — | — | WO | disclosed |
| US-20140148400-A1 | CARBONIC ANHYDRASE INHIBITORS WITH ANTIMETASTATIC ACTIVITY | METASIGNAL THERAPEUTICS INC. (CA) | 2014-05-29 | — | — | US | disclosed |
| US-20140148400-A1 | CARBONIC ANHYDRASE INHIBITORS WITH ANTIMETASTATIC ACTIVITY | METASIGNAL THERAPEUTICS INC. (CA) | 2014-05-29 | — | — | US | disclosed |
| US-20140148400-A1 | CARBONIC ANHYDRASE INHIBITORS WITH ANTIMETASTATIC ACTIVITY | METASIGNAL THERAPEUTICS INC. (CA) | 2014-05-29 | — | — | US | disclosed |
| WO-2013028664-A1 | PSMA IMAGING AGENTS | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2013-02-28 | — | — | WO | disclosed |
| CN-102898408-A | Benzopyran compounds, preparation method and applications thereof | SHANGHAI RUIGUANG BIOCHEMICAL SCIENCE AND TECHNOLOGY DEV CO LTD | 2013-01-30 | — | — | CN | disclosed |
| WO-2012070024-A1 | CARBONIC ANHYDRASE INHIBITORS WITH ANTIMETASTATIC ACTIVITY | METASIGNAL THERAPEUTICS INC. (CA) | 2012-05-31 | — | — | WO | disclosed |
| WO-2012070024-A1 | CARBONIC ANHYDRASE INHIBITORS WITH ANTIMETASTATIC ACTIVITY | METASIGNAL THERAPEUTICS INC. (CA) | 2012-05-31 | — | — | WO | disclosed |
| US-4151291-A | ANALGESICS | UNICLER (FR) | 1979-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250215028-A1 | SYNTHETIC GLYCEROPHOSPHOLIPIDS COMPRISING AT LEAST ONE REACTIVE FUNCTION, PROCESS FOR PREPARING SAME AND USES THEREOF IN DIFFERENT APPLICATIONS | PHOSPHO1, SGMS1, SGPL1 | CA12 3771/4885CA9 3769/4885CA1 3328/4885 |
| US-20140148400-A1 | CARBONIC ANHYDRASE INHIBITORS WITH ANTIMETASTATIC ACTIVITY | CA7, CA4, CA2 | CA12 10/4885CA9 4/4885CA1 5/4885 |
| US-11862764-B2 | Non-aqueous electrolyte comprising additive for non-aqueous electrolyte, and lithium secondary battery comprising the same | SLC9A1, SLC26A3, RER1 | CA12 923/4885CA9 690/4885CA1 552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.